MDGL

About Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) closed the 2026-09-16 session at $526.52, up 0.62% versus the previous close (+3.26). The stock opened at $523.00 and traded between $517.45 and $529.32 during that session. Session trading volume was 125K shares. The volume-weighted average price (VWAP) is $524.21.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals, Inc. Common Stock has a market capitalization of $12.09 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MDGL is listed on the XNAS exchange. The company employs approximately 915 people. Madrigal Pharmaceuticals, Inc. Common Stock is headquartered in WEST CONSHOHOCKEN, PA. The recorded listing date is 2007-02-06.

On this page you can find market MDGL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.